TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02282956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,75%
Description: Ropivacaine injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior tibial nerve block
Description: ultrasound guided posterior tibal nerve block
Study: NCT02720627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cortexolone 17α-propionate
Description: CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
Study: NCT00865176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg Tablets Sandoz Inc., USA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspra 50 mg Tablets GD Searle LLC, USA
Study: NCT04132817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: specified dose on specified days
Study: NCT02576106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Study: NCT02097316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: usual insulin pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: usual insulin pump
Study: NCT00860301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
Study: NCT02282956

Intervention type: DRUG
Group type: OTHER
Intervention: morphine and droperidol
Description: i.v PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine and droperidol
Description: i.v PCA
Study: NCT02963649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB
Description: Drug Coated Balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: Percutaneous Transluminal Angioplasty
Study: NCT02521337

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT03439371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLA-mismatched micro-transplantation after induction chemotherapy
Description: HLA-mismatched micro-transplantation after induction chemotherapy
Study: NCT05952622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous passive motion therapy
Description: Patients will be supplied with a continuous passive motion device which will allow additional individual treatment of the affected shoulder for 6 weeks.
Study: NCT02280135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of Autologous bone marrow Stem Cell
Description: We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Subconjunctival injection of saline
Description: In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.
Study: NCT02865915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLE4901
Description: For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match active drug
Study: NCT03863028

Intervention type: OTHER
Intervention: Simulation training
Description: It is not a randomized trial - all three groups are exposed to simulation training.
Study: NCT02521337

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT01569399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: Frequency (10hz) 120% motor threshold 10 sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: Frequency (10hz) 120% motor threshold 10 sessions
Study: NCT02822092

Intervention type: DRUG
Intervention: Risperidone or Aripiprazole (patients only)
Description: Inpatients deemed eligible for the study, we be put on open-label risperidone
Study: NCT04552444

Intervention type: DRUG
Intervention: Biapenem
Description: In the course of CRKP treatment, double dose biapenem was selected.

Intervention type: DRUG
Intervention: Biapenem
Description: In the course of CRKP treatment, double dose biapenem was selected.
Study: NCT01929616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
Study: NCT00796575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8080
Description: CS-8080 1mg tablets, 3 tablets administered 1 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: placebo tablets matching active
Study: NCT03098342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue-mediated photodynamic therapy
Description: Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amorolfine 5% Nail Lacquer
Description: Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
Study: NCT04248595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
Study: NCT00128921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE™
Description: Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE™
Description: Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE™
Description: Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.
Study: NCT04599296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip brace
Description: Hip brace
Study: NCT02876965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Stretching
Description: Subjects completed one stretching session on the main muscle groups of the body weekly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
Study: NCT00443586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Screening
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental Screening
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Screening
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Screening
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
Study: NCT00796575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8080
Description: CS-8080 5 mg tablets, 2 tablets administered 1 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8080
Description: CS-8080 5 mg tablets, 4 tablets administered 1 times per day
Study: NCT01017055

Intervention type: OTHER
Intervention: Voice and Swallowing evaluations
Description: Fiberoptic exam to evaluate vocal cord and swallowing function
Study: NCT00391794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Stage Memory Loss Support Group
Description: 8 week support group led by trained facilitators

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Seminar
Description: 4 hour education session led by trained facilitators
Study: NCT02836184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic Acids
Description: Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium Carbonate 500mg per oral, twice a day
Study: NCT01432223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 260mg/m2 q3w
Study: NCT02501876

Intervention type: OTHER
Intervention: There is a retrospectiv observational study. No intervention
Description: There is a retrospectiv observational study. No intervention will be performed

Intervention type: OTHER
Intervention: There is a retrospectiv observational study. No intervention
Description: There is a retrospectiv observational study. No intervention will be performed
Study: NCT00443586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening plus Transportation
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
Study: NCT04335474

Intervention type: PROCEDURE
Intervention: Surgical drainage strategy
Description: A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.

Intervention type: PROCEDURE
Intervention: Percutaneous drainage strategy
Description: The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
Study: NCT01801202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LightSheer Duet HS handpiece
Description: The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
Study: NCT03090204

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound measurements
Description: ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
Study: NCT01377545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic given via perineural catheter for infraclavicular nerve block.
Description: Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic given via needle for infraclavicular nerve block
Description: Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
Study: NCT03450473

Intervention type: DEVICE
Group type: OTHER
Intervention: SurgiMend® MP
Description: SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
Study: NCT04290455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microblepharoexfoliative procedure with BlephEx™
Description: The device will be used to clean both upper and lower eyelid in the office visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid cleansing with eyelid wipes (Optase)
Description: Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily eyelid cleansing with eyelid wipes (Optase)
Description: Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily eyelid cleansing with eyelid wipes (Optase)
Description: Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
Study: NCT02074007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR01
Description: drops administered as needed for pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Glycerin ear drops (placebo) drops administered as needed for ear pain
Study: NCT01979991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Imaging and Reconstruction
Description: Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used.
Study: NCT04379427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanmina Biosensor
Description: non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanmina Biosensor
Description: non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sanmina Biosensor
Description: non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.
Study: NCT03377374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five drops of Placebo taken twice a day (in the morning and in the evening).
Study: NCT02756208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300 ug FLSC vaccine
Description: FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 150 ug FLSC vaccine
Description: FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 75 ug FLSC vaccine
Description: FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
Study: NCT02657928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO